Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Healthtrust
Argus Health
Accenture
Daiichi Sankyo
Citi
Teva
Boehringer Ingelheim
Moodys
Merck

Generated: December 15, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR VARENICLINE TARTRATE

« Back to Dashboard

Clinical Trials for Varenicline Tartrate

Trial ID Title Status Sponsor Phase Summary
NCT00141167 A Twelve-Week Study of Varenicline for Safety and Efficacy in Comparison With Placebo for Smoking Cessation Completed Pfizer Phase 3 The primary purpose of this study is to evaluate the safety and efficacy of varenicline given for a twelve week treatment period in comparison with placebo for smoking cessation.
NCT00141206 A Twelve-Week Study of Varenicline for Safety and Efficacy in Comparison With Placebo and Zyban for Smoking Cessation Completed Pfizer Phase 3 The primary purpose of this study is to evaluate the safety and efficacy of varenicline given for a twelve week treatment period in comparison with placebo and Zyban for smoking cessation.
NCT00143299 A 52-Week Placebo-Controlled Study Evaluating the Safety of Varenicline Completed Pfizer Phase 3 The primary purpose of this study is to obtain safety information on cigarette smokers treated with 52 weeks of varenicline regardless of smoking status.
NCT00143325 An Open Label Study That Compares Varenicline to Transdermal Nicotine Patch for Smoking Cessation Completed Pfizer Phase 3 Open-label comparison of standard 12-week regimen of varenicline with standard 10-week regimen of transdermal nicotine patch for smoking cessation.
NCT00143364 A Twelve-Week Study of Varenicline for Safety and Efficacy in Comparison With Placebo and Zyban for Smoking Cessation Completed Pfizer Phase 3 The primary purpose of this study is to evaluate the safety and efficacy of varenicline given for a twelve week treatment period in comparison with placebo and Zyban for smoking cessation.
NCT00282984 Efficacy and Safety of Varenicline in Smokers With Cardiovascular Disease Who Wish to Quit Smoking Completed Pfizer Phase 3 The primary purpose of this study is to determine whether or not varenicline will help people with cardiovascular disease quit smoking and to confirm it is safe in these patients.
NCT00285012 Smoking Cessation in Subjects With Mild-to-moderate Chronic Obstructive Pulmonary Disease (COPD). Completed Pfizer Phase 3 This study is to be conducted in subjects with mild-to-moderate COPD who are cigarette smokers with the intent of demonstrating differences in smoking cessation between varenicline and placebo.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Varenicline Tartrate

Condition Name

Condition Name for Varenicline Tartrate
Intervention Trials
Smoking Cessation 20
Smoking 2
Schizophrenia 2
Alzheimer's Disease 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Varenicline Tartrate
Intervention Trials
Schizophrenia 3
Problem Behavior 2
Mental Disorders 2
Tobacco Use Disorder 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Varenicline Tartrate

Trials by Country

Trials by Country for Varenicline Tartrate
Location Trials
United States 165
South Africa 20
Canada 16
Mexico 15
Brazil 13
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Varenicline Tartrate
Location Trials
Massachusetts 11
California 10
Pennsylvania 9
New York 8
Connecticut 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Varenicline Tartrate

Clinical Trial Phase

Clinical Trial Phase for Varenicline Tartrate
Clinical Trial Phase Trials
Phase 4 9
Phase 3 9
Phase 2/Phase 3 1
[disabled in preview] 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Varenicline Tartrate
Clinical Trial Phase Trials
Completed 28
Withdrawn 1
Active, not recruiting 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Varenicline Tartrate

Sponsor Name

Sponsor Name for Varenicline Tartrate
Sponsor Trials
Pfizer 25
National Heart, Lung, and Blood Institute (NHLBI) 1
Universita degli Studi di Catania 1
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Varenicline Tartrate
Sponsor Trials
Industry 27
Other 9
NIH 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Teva
Mallinckrodt
Harvard Business School
McKesson
Dow
Colorcon
Merck
Baxter
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.